Exelixis, Inc. EXEL

Healthcare · Biotechnology · valued as of 2026-11-02 · statements 2025-12-31

Average Intrinsic Value
$5.47B
Market Cap
$14.37B
Margin of Safety
-162.9%
Intrinsic / Market Ratio
0.38

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

8.36B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

6.19B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

1.85B USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

5.47B USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

5.47B USD

from the sum above

Market Cap

14.37B USD

today's price times the shares

Intrinsic Value ÷ Market Cap

0.38×

the ratio the screener ranks by; Margin of Safety -162.9% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 8.36B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)6.08B USD
+②Net Cash Today674.13M USD
+③Growth Value1.60B USD
=Value8.36B USD

EPV of the Operations (NOPAT over WACC)

6.08B USD

Net cash today

+674.13M USD

Growth Value

+1.60B USD

Value

8.36B USD

①EPV (earnings power value)

6.08B USD

②Net Cash Today

674.13M USD

③Growth Value

1.60B USD

Market value

Market Cap14.37B USD

Today's price times the shares.

Value vs market

Margin of Safety-71.9%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 6.19B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE5.63B USD
+②Equity at Year 15, Today567.71M USD
=Value6.19B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

5.63B USD

②Equity at Year 15, Today

567.71M USD

Market value

Market Cap14.37B USD

Today's price times the shares.

Value vs market

Margin of Safety-132.0%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 1.85B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).

The projection was not made (an FCFF at or below zero in the latest three years), so the value is the book value today, 1.85B USD, as the screener leaves it.

①Present Value of the 15 Years of FCFF

Not in the value

②Invested Capital at Year 15, Today

Not in the value

③Net Cash Today

Not in the value

Market value

Market Cap14.37B USD

Today's price times the shares.

Value vs market

Margin of Safety-678.7%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 7.00%
weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.42×Market Risk Premium 6.00%= 7.03%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 158.79M USDPretax Income 942.15M USD= 16.85%

The tax the interest saves.

Interest Expense =EBIT 893.59M USD−Pretax Income 942.15M USD= —

The interest the company paid: EBIT is the profit before tax plus the interest.

No interest is read: it needs debt and an EBIT above the profit before tax, the gap between them being the interest. Without it the cost of debt takes the 4% default.

Cost of Debt 4.00% (default): with no debt or no interest read, the 4% default after tax stands for what the lenders are paid a year.

Debt Weight =Total Debt 166.09M USDMarket Cap + Total Debt 14.37B USD + 166.09M USD= 1.14%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 98.86%×Cost of Equity 7.03%+Debt Weight 1.14%×Cost of Debt 4.00%= 7.00%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2026-06-30.

Total Assets 2.50B USD − Total Liabilities 651.12M USD = Book Value Today 1.85B USD

Total Debt 166.09M USD − Cash and Short-Term Investments 840.22M USD = Net Debt Today -674.13M USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 1-17.8%at most 5%passes248,885,000 / 302,793,000
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets4.1%at least -10.0%passes(885.15M USD − 783.35M USD) ÷ 2.50B USD
Price to bookMarket Cap ÷ Book Value Today7.79×at most 3×does not pass14.37B USD ÷ 1.85B USD
Operating marginOperating Income ÷ Revenue38.5%above 10.0%passes893.59M USD ÷ 2.32B USD
Revenue growthRevenue ÷ Revenue a Year Before − 17.0%above 10.0%does not pass2.32B USD / 2.17B USD
Net cash(Cash − Total Debt) ÷ Market Cap0.8%above -30%passes(281.73M USD − 166.09M USD) ÷ 14.37B USD
Operating efficiencyOperating Income ÷ Gross Profit39.9%above 25.0%passes893.59M USD ÷ 2.24B USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Market data
The data provider's own ratios and the analysts' consensus, read beside the valuation, never in it.

Share price

58 USD

Enterprise value

13.70B USD

market cap plus net debt

EV / EBITDA

13.41×

Price / book

7.82×

the provider's book

Price / earnings

18.22×

Return on equity

44.4%

the provider's, not the engine's

Profit margin

35.3%

Revenue growth

10.6%

Analyst target, mean

54 USD

Analysts

15

opinions in the consensus

Financial Statements

The income statement, the balance sheet and the cash flow the screener holds, year by year, in USD.

Financial statements, year by year
The annual lines the screener holds today, in USD at each period's rate; the figures this valuation read are in its calculation above.
USD2022202320242025
Income statement

Revenue

1.61B1.83B2.17B2.32B

Gross profit

1.55B1.76B2.09B2.24B

Operating income

201.69M171.06M690.64M893.59M

EBITDA

operating income before depreciation and amortisation

222.58M196.80M719.47M922.68M

Pretax income

234.59M257.78M682.32M942.15M

Net income

182.46M207.97M521.79M783.35M

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

182.46M207.97M587.13M800.41M

R&D

892.70M1.05B911.32M825.83M
Balance sheet, year end

Total assets

3.07B2.95B2.95B2.85B

Total liabilities

583.65M679.12M704.19M683.79M

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

2.49B2.27B2.25B2.16B

Total debt

190.36M190.13M191.01M173.21M

Cash and equivalents

501.70M263.26M217.59M482.97M

Net PP&E

fixed assets after depreciation

401.60M471.32M359.47M441.71M

Working capital

current assets less current liabilities

1.30B924.60M1.06B1.04B
Cash flow

Operating cash flow

362.98M333.66M700.67M885.15M

Capital expenditure

paid out, so below zero

-138.59M-163.13M-66.25M-39.97M

Depreciation and amortisation

20.90M25.74M28.83M29.08M

Free cash flow

operating cash flow plus capital expenditure

224.38M170.53M634.42M845.18M